Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLXBiotechnology
+$0.14 today
- Market cap
- $3.37B
- Beta
- -0.16
- P/E (TTM)
- -11.3
- EPS (TTM)
- -$1.36
Volume 1.76M
Average 1.21M
Returns on capital
Amylyx Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-47.4%
avg -13.9%
ROIC
-49.3%
avg 11.2%
ROA
-43.5%
avg -154.8%
Analysis
ROA is currently the strongest return metric at -43.5% versus its period average of -154.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Justin Klee | Co-CEO & Director | USD 1.25M | 35 | — | — |
Joshua Cohen | Co-Founder, Co-CEO & Director | USD 1.25M | 34 | — | — |
Camille L. Bedrosian | Chief Medical Officer | USD 1.01M | 73 | 278.06K | 0.33% |
James Frates | Chief Financial Officer | USD 817.18K | 59 | — | — |
Gina Mazzariello | Chief Legal Officer & General Counsel | USD 715.49K | 54 | 190.84K | 0.23% |
Machelle Manuel | Vice President & Head of Global Medical Affairs | — | — | — | — |
Tom Holmes | Chief Technical Operations Officer | — | — | — | — |
Linda A. Arsenault | Chief Human Resources Officer | — | — | — | — |
Lindsey Allen | Head of Investor Relations & Communications | — | — | — | — |
Tammy Sarnelli | Global Head of Regulatory Affairs | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 10, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$152,183.00
Sells
39
$17.31M
Net Transaction Value
−$17.16M
Net selling
Most Active
FRATES JAMES M
9 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 10, 26Nov 10, 2026 | FRATES JAMES M Direct | Sell | $388.1K$388,107.52 |
| Nov 10, 26Nov 10, 2026 | FRATES JAMES M Direct | Sell | $223K$222,982.56 |
| Nov 9, 26Nov 9, 2026 | Klee Justin B. Direct | Sell | $1.9M$1,882,149.31 |
| Nov 9, 26Nov 9, 2026 | Cohen Joshua B Direct | Sell | $1.1M$1,120,031.70 |
| Nov 9, 26Nov 9, 2026 | Cohen Joshua B Direct | Sell | $1.9M$1,863,646.07 |
| Nov 9, 26Nov 9, 2026 | Klee Justin B. Direct | Sell | $1.1M$1,101,689.09 |
| Nov 9, 26Nov 9, 2026 | FRATES JAMES M Direct | Sell | $226.3K$226,292.99 |
| Nov 9, 26Nov 9, 2026 | FRATES JAMES M Direct | Sell | $370.4K$370,359.15 |
| Oct 5, 26Oct 5, 2026 | MILNE GEORGE M JR Direct | Sell | $830.9K$830,904.00 |
| Sep 10, 26Sep 10, 2026 | Klee Justin B. Direct | Sell | $47.7K$47,710.33 |
1–10 of 41
Summary
Insiders reported 2 buys worth $152,183.00 and 39 sells worth $17.31M over the last 12 months. That adds up to net selling of $17.16M. FRATES JAMES M was the most active insider with 9 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Amylyx Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about AMLX's management, answered from reported figures.
Who manages AMLX?
Amylyx Pharmaceuticals, Inc. (AMLX) lists 10 active executives. The top listed executive is Justin Klee, Co-CEO & Director.
Are AMLX insiders buying or selling?
Recent insider activity shows net buying of $16.00M.
Continue the stock analysis
Jump to another research area for this company.